Evacetrapib
Evacetrapib is a potent and selective of CETP inhibitor, which inhibits human recombinant CETP protein (IC50 5.5 nM) and CETP activity in human plasma (IC50 36 nM) in vitro.
Product Specifications
CAS Number
1186486-62-3
Product Name Alternative
LY2484595
UNSPSC
12352005
Hazard Statement
H361, H400, H410
Target
CETP
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/Evacetrapib.html
Concentration
10mM
Purity
98.89
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C([C@H]1CC[C@H](CN2CCC[C@H](N(CC3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)C4=NN(C)N=N4)C5=CC(C)=CC(C)=C52)CC1)O
Molecular Formula
C31H36F6N6O2
Molecular Weight
638.65
Precautions
H361, H400, H410
References & Citations
[1]Cao G, et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res. 2011 Dec;52 (12) :2169-76.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC042425-500 1x 500 µL
BOB.1 (B-Cell Marker) (BOB1/2425), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
